Compare Abeona Therapeutics Inc (ABEO) vs Abercrombie & Fitch Co. (ANF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Abercrombie & Fitch Co. — how do they compare? Abeona Therapeutics Inc trades at $7.32 (market cap $424.33M), while Abercrombie & Fitch Co. trades at $120 (market cap $5.27B). The key difference: Abercrombie & Fitch Co. is far larger — about 12.4× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Abercrombie & Fitch Co. nearer its low. Which is the better fit depends on your goals.
| ABEO | ANF | |
|---|---|---|
Market Cap | $424.33M | $5.27B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.45 | $129.85 |
52-Week Low | $4.17 | $65.61 |
Enterprise Value | $279.23M | $5.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Abercrombie & Fitch (ANF) trades at $112.62, up 1.94% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $4.95B and net income of $566.22M, achieving consistent earnings beats in recent quarters. Valuation remains attractive with P/E of 10.89 and EV/EBITDA of 6.54, while profitability metrics show impressive ROE of 39.04% and net margin of 9.34%.
ANF presents a compelling investment case with strong operational performance and reasonable valuation, though technical indicators show overbought conditions. Key risks include retail sector volatility and potential growth headwinds in EMEA markets. Analyst consensus leans neutral with 50% hold ratings, while institutional ownership trends show continued interest from major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Abercrombie & Fitch Co.
Abercrombie & Fitch Co is a specialty retailer that sells casual clothing, personal-care products, and accessories for men, women, and children. It sells direct to consumer through its stores and websites, which include the Abercrombie & Fitch, Abercrombie kids, and Hollister brands. Most stores are in the United States, but the company does have many stores in Canada, Europe, and Asia. All stores are leased. Abercrombie ships to well over 100 countries via its websites. The company sources its merchandise from dozens of vendors that are primarily located in Asia and Central America. Abercrombie has two distribution centers in Ohio to support its North American operations. It uses third-party distributors for sales in Europe and Asia.
Read more on ANF →
